DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160778

Mepolizumab: a new drug in asthma armamentorium

Satyadeo Choubey, Kunal Ahuja

Abstract


Bronchial asthma is a syndrome characterized by airflow obstruction that varies markedly, both spontaneously and with treatment. The current therapy for asthma includes either inhaled corticosteroids alone or in combinations with inhaled bronchodilators with other controller options being theophyllines, leukotriene antagonists and systemic corticosteroids. In step V of Global Initiative for Asthma (GINA) management guidelines Anti Ig E, Omalizumab is recommended in selected patients when everything fails. But still some unmet need is felt in the form of refractory asthma. Mepolizumab, an IL-5 antagonist has been developed in this regard and has been approved by FDA on Nov 4, 2015 followed by European commission on Dec 02, 2015 in view of good results based on clinical trials conducted by GlaxoSmithKline a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. This article covers the review of mepolizumab with its advantages in refractory bronchial asthma.

Keywords


Asthma, Anti IL-5, Mepolizumab

Full Text:

PDF

References


http://www.who.int/mediacentre/factsheets/fs307/e/ (last accessed 30/12/2015).

http://www.ginasthma.org/documents/5/documents_variants/59 (last accessed 30/12/2015).

Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci. 1999;36:453-96.

O 'Byrne PM. The demise of anti-IL-5 for asthma, or not. Am. J. Respir. Crit Care Med. 2007;176:1059-60.

Barnes PJ. Pathophysiology of allergic inflammation. Immunol. Rev. 2011;242:31-50.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf (last accessed 30/12/2015).